Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial

Koren, G and Clark, S and Hankins, GDV and Caritis, SN and Umans, JG and Miodovnik, M and Mattison, DR and Matok, I (2015) Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. BMC Pregnancy and Childbirth, 15 (1).

Preview	PDF Published Version Available under License : See the attached license file. Download (346kB) | Preview
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo. Methods: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing. Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement. Conclusions: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy. Trial Registration: Clinical Trial Registration No: NCT00614445.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID Koren, G Clark, S Hankins, GDV Caritis, SN caritiss@pitt.edu CARITISS Umans, JG Miodovnik, M Mattison, DR Matok, I
Date:	18 March 2015
Date Type:	Publication
Journal or Publication Title:	BMC Pregnancy and Childbirth
Volume:	15
Number:	1
DOI or Unique Handle:	10.1186/s12884-015-0488-1
Schools and Programs:	School of Medicine > Obstetrics, Gynecology, and Reproductive Sciences
Refereed:	Yes
Date Deposited:	31 Aug 2016 16:08
Last Modified:	30 Mar 2021 10:55
URI:	http://d-scholarship.pitt.edu/id/eprint/29391

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

---

Actions (login required)

View Item